2022 annual financial data
Inhibikase Therapeutics 2022 Financial results
Direct answer
Revenue was 123,440 USD.
Operating income was -18,128,608 USD and net income was -18,054,155 USD.
Operating cash flow was -17,351,103 USD.
Get free Inhibikase Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 123,440 USD
- Operating income
- -18,128,608 USD
- Net income
- -18,054,155 USD
- Operating cash flow
- -17,351,103 USD
Explore related company data
View all 2022 financial metricsView RevenueView Operating incomeView Net incomeView Operating cash flowView Revenue growthView Operating income growthView Net income growthView Operating cash flow growthView Operating marginView Net marginView Operating cash flow marginView all Inhibikase Therapeutics financial years